Core Insights - RespireRx Pharmaceuticals Inc. has received a grant of $1,499,869 from the NIH/NINDS to support the development of its lead GABAkine, KRM-II-81, for the treatment of epilepsy [2][17] - The company has entered into an Amended and Restated Patent License Agreement with the University of Wisconsin Research Foundation to enhance its neuromodulator programs [3][6] Grant Details - The NIH/NINDS grant is awarded under the Small Business Innovation Research (SBIR) program, covering the budget period from September 23, 2025, to August 31, 2026, with a total requested amount of $2,999,738 over two years [2][17] - The project aims to complete preclinical toxicology studies to support the filing of an investigational new drug application (IND) for KRM-II-81 [2][17] Patent License Agreement - The Amended and Restated Patent License Agreement includes updates on regulatory milestone payments, royalty structures, and patent cost reimbursements [6][7] - The agreement eliminates prior equity provisions in favor of a fixed exit fee tied to liquidity events, streamlining diligence and reporting obligations [6][7] Product Development - KRM-II-81 has shown significant anti-seizure activity across 34 preclinical models, with no development of pharmaco-resistance or tolerance [4][14] - The compound has also demonstrated analgesic properties comparable to commonly used analgesics without the side effects associated with opioids [5][16] Company Overview - RespireRx Group focuses on developing treatments for psychiatric and neurological disorders, including epilepsy, pain, ADHD, and obstructive sleep apnea [8][9] - The company holds exclusive licenses and patents for various chemical compounds aimed at treating a range of disorders [9] Future Directions - EndeavourRx LLC will continue to focus on the development of KRM-II-81 and other GABAkines for neurological and psychiatric disorders [3][13] - The company is also advancing its AMPAkines programs, which have shown promise in treating CNS-driven neurobehavioral and cognitive disorders [10][12]

Core Insights - RespireRx Pharmaceuticals Inc. has received a grant of $1,499,869 from the NIH/NINDS to support the development of its lead GABAkine, KRM-II-81, for the treatment of epilepsy [2][17] - The company has entered into an Amended and Restated Patent License Agreement with the University of Wisconsin Research Foundation to enhance its neuromodulator programs [3][6] Grant Details - The NIH/NINDS grant is awarded under the Small Business Innovation Research (SBIR) program, covering the budget period from September 23, 2025, to August 31, 2026, with a total requested amount of $2,999,738 over two years [2][17] - The project aims to complete preclinical toxicology studies necessary for filing an investigational new drug application (IND) for KRM-II-81 [2][17] KRM-II-81 Development - KRM-II-81 has shown significant anti-seizure activity across 34 preclinical models, demonstrating no development of pharmaco-resistance or tolerance [4][14] - The compound has also been effective in reducing epileptiform electrical activity in brain slices from treatment-resistant epileptic patients [4][15] Analgesic Properties - KRM-II-81 exhibits strong analgesic effects in various preclinical studies, comparable to or exceeding commonly used analgesics, without the side effects associated with opioids [5][16] - The compound does not induce tolerance, dependence, or respiratory depression, addressing concerns related to the opioid epidemic [5][16] Patent License Agreement - The Amended and Restated Patent License Agreement includes updates on regulatory milestone payments, royalty structures, and patent cost reimbursements [6][7] - The agreement aims to align with current commercialization strategies and eliminate prior equity provisions in favor of a fixed exit fee [6][7] Company Overview - RespireRx Group focuses on developing treatments for psychiatric and neurological disorders, including epilepsy, pain, ADHD, and obstructive sleep apnea [8][9] - The company holds exclusive licenses and patents for various chemical compounds targeting these conditions [9] Additional Programs - The company is also advancing its AMPAkines programs, which have shown promise in treating CNS-driven neurobehavioral and cognitive disorders [10][12] - ResolutionRx Ltd, a subsidiary, is developing a new formulation of dronabinol for obstructive sleep apnea, with a total budget of approximately $16.5 million [19][20]

Glen Rock, N.J., Nov. 18, 2025 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce the commencement of a Regulation D, Rule 506(c) exempt offering of securities, across the three entities of the RespireRx Group, RespireRx, EndeavourRx LLC and ResolutionRx Ltd (collectively, the RespireRx Group). The targeted ...

Glen Rock, N.J., Nov. 18, 2025 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (“RespireRx”, “RSPI”, “Respondent” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, announces the receipt of an Order Making Findings and Revoking Registration of Securities Pursuant to Section 12(j) of the Securities Exchange Act of 1934. The Order On November 13, 2025, effective November 14, 2025 the Securiti ...